All In Biotech

Drug Trial Radar · NCT05503264

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Basket Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 122 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

122

Actual

Start

Sep 27, 2022

Primary completion

Dec 16, 2026

Study completion Dec 14, 2028

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Chugai Pharmaceutical
First posted
Aug 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.

Conditions

  • NMDAR Autoimmune Encephalitis
  • LGI1 Autoimmune Encephalitis

Interventions

  • SatralizumabDrug

    In Part 1, study drug will be administered after all other study-related procedures have been performed at a site visit at Weeks 0, 2, 4, and every 4 weeks (Q4W) thereafter. Participants will receive satralizumab according to body weight, administered as subcutaneous (SC) injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit. In Part 2, participants will be asked to choose from one of the following options: Option 1: continue on randomized, double-blind study drug; Option 2: start open-label satralizumab based on body weight; Option 3: stop study treatment and continue follow-up assessments. As of Protocol Version 6, participants in the NMDAR cohort who chose Option 1 will transition to either Option 2 or Option 3 at the time of the primary analysis.

  • PlaceboOther

    Satralizumab placebo prefilled syringe (PFS) is identical in composition to satralizumab PFS, but does not contain the satralizumab active ingredient and will be identical in appearance and packaging to satralizumab. A PFS (assembled with an needle safety device \[NSD\] and extended finger flange) filled with 0.5 milliliters (mL) of solution, corresponding to 60 milligrams (mg) satralizumab, may be used in Part 2 once it becomes available at the study site.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Proportion of Participants in NMDAR AIE Cohort With Modified Rankin Scale (mRS) Score Improvement ≥ 1 From Baseline and no Use of Rescue Therapy at Week 24Time frame: Baseline up to Week 24
  2. Part 1: Proportion of Participants in LGI1 AIE Cohort With mRS Score Improvement ≥ 1 From Baseline and no Use of Rescue Therapy at Week 52Time frame: Baseline up to Week 52
  3. Part 2: Percentage of Participants With Adverse Events (AEs)Time frame: From Week 52 up to 4 years

Locations

56 sites in 15 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Hoag Memorial Hospital

    Newport Beach, California

  • UCSF- Multiple Sclerosis Centre

    San Francisco, California

  • University of Colorado

    Aurora, Colorado

  • Childrens National Health Center

    Washington D.C., District of Columbia

  • Brigham and Women's Hospital Department of Neurology

    Boston, Massachusetts

  • Mayo Clinic - Rochester

    Rochester, Minnesota

  • NYU-Langone Medical Center

    New York, New York

  • University Hospitals of Cleveland

    Cleveland, Ohio

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Hospital Ramos Mejía

    CABA, Argentina

  • Hospital Britanico

    Ciudad Autonoma Bs As, Argentina

  • Sanatorio del Sur S.A.

    San Miguel de Tucumán, Argentina

  • Hospital Geral de Fortaleza

    Fortaleza, Ceará, Brazil

  • CEDOES - Diagnóstico e Pesquisa

    Vitória, Espírito Santo, Brazil

  • Instituto de Neurologia de Curitiba

    Curitiba, Paraná, Brazil

  • Centro de Pesquisas Clinicas

    São Paulo, São Paulo, Brazil

  • Hospital Israelita Albert Einstein

    São Paulo, São Paulo, Brazil

  • Beijing Children's Hospital, Capital Medical University

    Beijing, China

  • Beijing Tongren Hospital

    Beijing, China

  • Beijing Tiantan Hospital,Capital Medical University

    Beijing, China

  • West China Hospital - Sichuan University

    Chengdu, China

  • Fujian Medical University Union Hospital

    Fuzhou, China

  • Affiliated Hospital of Jining Medical University

    Jining, China

  • Huashan Hospital, Fudan University

    Shanghai, China

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, China

  • Fakultni nemocnice v Motole

    Prague, Czechia

  • Odense Universitetshospital, Neurologisk Afdeling N

    Odense C, Denmark

  • Hopital neurologique Pierre Wertheimer - CHU Lyon

    Bron, France

  • Hopital Pitié Salpétrière - CHU

    Paris, France

  • Komfo Anokye Teaching Hospital

    Kumasi, Ghana

  • Hadassah University Hospital Ein Kerem

    Jerusalem, Israel

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel

  • A. O. U. Federico II

    Naples, Campania, Italy

  • Irccs A.O.U.San Martino Ist

    Genoa, Liguria, Italy

  • Fondazione Istituto Neurologico Mondino IRCCS

    Pavia, Lombardy, Italy

  • AOU Policlinico Giaccone

    Palermo, Sicily, Italy

  • Fujita Health University Hospital

    Aichi, Japan

  • Chiba University Hospital

    Chiba, Japan

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.